JP2017506505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506505A5 JP2017506505A5 JP2016549076A JP2016549076A JP2017506505A5 JP 2017506505 A5 JP2017506505 A5 JP 2017506505A5 JP 2016549076 A JP2016549076 A JP 2016549076A JP 2016549076 A JP2016549076 A JP 2016549076A JP 2017506505 A5 JP2017506505 A5 JP 2017506505A5
- Authority
- JP
- Japan
- Prior art keywords
- binding agent
- seq
- agent according
- cdr3
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011230 binding agent Substances 0.000 claims description 66
- 102000003840 Opioid Receptors Human genes 0.000 claims description 24
- 108090000137 Opioid Receptors Proteins 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 102000005962 receptors Human genes 0.000 claims description 13
- 108020003175 receptors Proteins 0.000 claims description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 5
- 108091006027 G proteins Proteins 0.000 claims description 4
- 102000030782 GTP binding Human genes 0.000 claims description 4
- 108091000058 GTP-Binding Proteins 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 102000051367 mu Opioid Receptors Human genes 0.000 claims description 4
- 108020001612 μ-opioid receptors Proteins 0.000 claims description 4
- 102000016979 Other receptors Human genes 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000007876 drug discovery Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 230000007781 signaling event Effects 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 3
- 101710122576 Isocitrate lyase 2 Proteins 0.000 claims 1
- 230000000707 stereoselective effect Effects 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461933742P | 2014-01-30 | 2014-01-30 | |
| US61/933,742 | 2014-01-30 | ||
| PCT/EP2015/051991 WO2015121092A1 (en) | 2014-01-30 | 2015-01-30 | Opioid receptor binding agents and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506505A JP2017506505A (ja) | 2017-03-09 |
| JP2017506505A5 true JP2017506505A5 (enExample) | 2018-03-08 |
| JP6687525B2 JP6687525B2 (ja) | 2020-04-22 |
Family
ID=52434839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549076A Active JP6687525B2 (ja) | 2014-01-30 | 2015-01-30 | オピオイド受容体結合剤およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10233241B2 (enExample) |
| EP (1) | EP3099707B1 (enExample) |
| JP (1) | JP6687525B2 (enExample) |
| AU (1) | AU2015217846B2 (enExample) |
| CA (1) | CA2936728C (enExample) |
| WO (1) | WO2015121092A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201014715D0 (en) | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
| WO2015121092A1 (en) | 2014-01-30 | 2015-08-20 | Vib Vzw | Opioid receptor binding agents and uses thereof |
| GB201601690D0 (en) | 2016-01-29 | 2016-03-16 | Heptares Therapeutics Ltd | G proteins |
| US11668021B2 (en) | 2017-05-09 | 2023-06-06 | Yale University | Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction |
| AU2017435322A1 (en) * | 2017-10-11 | 2020-04-30 | Nanjing Legend Biotech Co., Ltd. | Compositions and methods for increasing protein half-life in a serum |
| CA3314168A1 (en) | 2019-04-29 | 2026-08-05 | Confo Therapeutics N.V. | Screening methods and assays for use with transmembrane proteins, in particular with gpcrs |
| WO2021140205A1 (en) | 2020-01-10 | 2021-07-15 | Confo Therapeutics N.V. | Methods for generating antibodies and antibody fragments and libraries comprising same |
| EP4019548A1 (en) * | 2020-12-23 | 2022-06-29 | Vrije Universiteit Brussel | Anti lag3 vhhs and their use |
| WO2026057805A1 (en) * | 2024-09-12 | 2026-03-19 | Universite De Geneve | Peptidic opioid receptor antagonists and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| US5882944A (en) * | 1993-06-23 | 1999-03-16 | The Regents Of The University Of California | Methods for G protein coupled receptor activity screening |
| FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| ATE374248T1 (de) | 1996-06-27 | 2007-10-15 | Vlaams Interuniv Inst Biotech | Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren |
| AU3596599A (en) | 1998-01-26 | 1999-08-09 | Unilever Plc | Method for producing antibody fragments |
| BR9916765A (pt) | 1999-01-05 | 2001-09-25 | Unilever Nv | Processo para produzir um material imunoadsorvente, uso de uma proteìna que é ligada por meio de uma ligação covalente a um fragmento de anticorpo, material imunadsorvente, uso de um material, e, kit de teste diagnóstico |
| ATE276359T1 (de) | 1999-01-19 | 2004-10-15 | Unilever Nv | Verfahren zur herstellung von antikörperfragmenten |
| CN1252264C (zh) | 1999-04-22 | 2006-04-19 | 荷兰联合利华有限公司 | 利用单价抗原－结合蛋白抑制病毒感染 |
| US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
| ATE440111T1 (de) | 1999-11-29 | 2009-09-15 | Bac Ip B V | Immobilisierte antigenbindende moleküle aus einer domäne |
| ATE342922T1 (de) | 1999-11-29 | 2006-11-15 | Unilever Nv | Immobilisierung von proteinen mit hilfe eines polypeptidsegments |
| ATE428733T1 (de) | 2000-03-14 | 2009-05-15 | Unilever Nv | Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen |
| US20030190598A1 (en) | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| AU2002229639A1 (en) | 2000-12-13 | 2002-06-24 | De Haard, Johannes Joseph Wilhelmus | Camelidae antibody arrays |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| JP4213586B2 (ja) | 2001-09-13 | 2009-01-21 | 株式会社抗体研究所 | ラクダ抗体ライブラリーの作製方法 |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| JP4323317B2 (ja) | 2001-12-21 | 2009-09-02 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） | 可変領域配列のクローニング方法 |
| WO2003055527A2 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| ATE444984T1 (de) | 2002-12-31 | 2009-10-15 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
| JP2008528010A (ja) | 2005-01-31 | 2008-07-31 | アブリンクス ナームローゼ フェンノートシャップ | 重鎖抗体の可変ドメイン配列を作出する方法 |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| LT2444424T (lt) | 2005-05-20 | 2018-10-25 | Ablynx N.V. | Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| CN101663319A (zh) | 2007-02-21 | 2010-03-03 | 埃博灵克斯股份有限公司 | 针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病 |
| MX2009012650A (es) | 2007-05-24 | 2010-02-18 | Ablynx Nv | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. |
| FR2916977A1 (fr) * | 2007-06-06 | 2008-12-12 | Engelhard Lyon Sa | STIMULATION DE LA SYNTHESE DES RECPTEURS MCR1, MCR2 ET µ OPIOIDE. |
| CA2749558C (en) | 2008-12-08 | 2019-01-15 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| CA2747644C (en) | 2008-12-19 | 2023-01-24 | Ablynx N.V. | Method for generation of immunoglobulin sequences |
| WO2011083140A1 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Immunoglobulin single variable domain directed against human cxcr4 |
| EP2611826B1 (en) | 2010-08-30 | 2016-09-21 | Confometrx, Inc. | Method and composition for crystallizing a family c gpcr |
| WO2012148586A1 (en) | 2011-03-15 | 2012-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Gpcr fusion protein containing an n-terminal autonomously folding stable domain, and crystals of the same |
| JP2014516963A (ja) | 2011-05-13 | 2014-07-17 | レセプトス インコーポレイテッド | Ｇタンパク質共役レセプターを結晶化するための新規融合パートナー |
| DK2951201T3 (en) | 2013-01-30 | 2018-01-08 | Vib Vzw | Novel chimeric polypeptides for screening and drug detection purposes |
| WO2015121092A1 (en) | 2014-01-30 | 2015-08-20 | Vib Vzw | Opioid receptor binding agents and uses thereof |
-
2015
- 2015-01-30 WO PCT/EP2015/051991 patent/WO2015121092A1/en not_active Ceased
- 2015-01-30 EP EP15701821.9A patent/EP3099707B1/en active Active
- 2015-01-30 JP JP2016549076A patent/JP6687525B2/ja active Active
- 2015-01-30 US US15/115,621 patent/US10233241B2/en active Active
- 2015-01-30 AU AU2015217846A patent/AU2015217846B2/en active Active
- 2015-01-30 CA CA2936728A patent/CA2936728C/en active Active
-
2019
- 2019-03-15 US US16/355,442 patent/US11352422B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Naved et al. | Kidney repair and regeneration: perspectives of the NIDDK (Re) Building a Kidney consortium | |
| RU2481355C2 (ru) | Аминокислотные последовательности, направленные на rank-l, и полипептиды, включающие их, для лечения заболеваний и нарушений костей | |
| JP2023524733A (ja) | 遺伝子発現を活性化及びサイレンシングするためのエフェクタードメインの作出、同定及び性質決定のための組成物、システム及び方法 | |
| Alexander et al. | Target highlights in CASP14: Analysis of models by structure providers | |
| ES2654675T3 (es) | Polipéptidos quiméricos novedosos para fines de examen y descubrimiento de fármacos | |
| US20100256341A1 (en) | Treatment of inflammation using alpha 7 receptor-binding cholinergic agonists | |
| US11008384B2 (en) | Anti-tenascin C antibodies and uses thereof | |
| RU2013153592A (ru) | Анти-mif антитела | |
| JP2013541335A5 (enExample) | ||
| HRP20170254T1 (hr) | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 | |
| Li et al. | Preparation of a chicken scFv to analyze gentamicin residue in animal derived food products | |
| BR112014010161A2 (pt) | anticorpo monoclonal antiproteína de ligação ao dna tar de 43 kda (tdp-43) e seus método de preparação e uso no tratamento de proteinopatia tdp-43, bem como composições, polinucleotídeo, método in vitro e kit para diagnosticar proteinopatia tdp-43 | |
| WO2022061594A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| WO2008031133A3 (en) | Borrelia antigens | |
| Kuai et al. | Characterization of binding mode of action of a blocking anti-platelet-derived growth factor (PDGF)-B monoclonal antibody, MOR8457, reveals conformational flexibility and avidity needed for PDGF-BB to bind PDGF receptor-β | |
| RU2013123270A (ru) | Структуры слитого белка шелка пауков для связывания с органической мишенью | |
| Wu et al. | Structure and analysis of nanobody binding to the human ASIC1a ion channel | |
| JP2021181450A (ja) | 細胞内抗原に対して向けられた単一ドメイン抗体 | |
| CN108350050A (zh) | 淀粉样蛋白β中的表位及其构象选择性抗体 | |
| CN111393529A (zh) | 与ox40l非竞争结合的抗ox40抗体 | |
| JP2024502091A5 (enExample) | ||
| WO2022037527A1 (zh) | 结合bcma的单可变结构域及抗原结合分子 | |
| US20250012808A1 (en) | Parallel antibody engineering compositions and methods | |
| JP2014509860A5 (enExample) | ||
| WO2006116442A3 (en) | Monoclonal antibodies and methods for their use in the detection of cervical disease |